| Followers | 35 |
| Posts | 2799 |
| Boards Moderated | 0 |
| Alias Born | 10/28/2013 |
Saturday, February 08, 2014 7:59:54 PM
More Antigens Better?
In addition to the synthetic vs natural antigen issue, there is the issue that it might not be reasonable to assume what the antigens are going to be. Clearly the scientist that developed ICT-107 believed they could make some assumptions about what antigens would be present, but even they believed that ICT-107 was not going to be effective for everyone.
More Antigens Better?
I want to try to logic through this:
1 Antigen, 10M DC's:
You had better pick the most common antigen.
Tumor Lysate, 10M DC's:
Assuming the cell mechanism for presenting internal proteins on the outer cell membrane does not discriminate, and or that the lysing process generates the same population/distribution; The most common antigen will be targeted by the most DC's. DC's for all antigens will be generated in proportion to how common the antigens are.
In Filter theory, the Wiener–Hopf equation shows that the best signal to noise you can get from a "noise filter" is by shaping the pass-band proportional to the signal to noise over that spectrum.
It's a little bit of a stretch... but I think it might be a meaningful analog. The same principals might say that the best you can do statistically in programming DC's is to program them in proportion to the antigen population. That is what a tumor lysate would do. That is what DCVax-L does, (given the two aforementioned assumptions).
Besides... Linda Lau apparently thought it was the best way to go or she would not have joined the team... for what that is worth.
In addition to the synthetic vs natural antigen issue, there is the issue that it might not be reasonable to assume what the antigens are going to be. Clearly the scientist that developed ICT-107 believed they could make some assumptions about what antigens would be present, but even they believed that ICT-107 was not going to be effective for everyone.
More Antigens Better?
I want to try to logic through this:
1 Antigen, 10M DC's:
You had better pick the most common antigen.
Tumor Lysate, 10M DC's:
Assuming the cell mechanism for presenting internal proteins on the outer cell membrane does not discriminate, and or that the lysing process generates the same population/distribution; The most common antigen will be targeted by the most DC's. DC's for all antigens will be generated in proportion to how common the antigens are.
In Filter theory, the Wiener–Hopf equation shows that the best signal to noise you can get from a "noise filter" is by shaping the pass-band proportional to the signal to noise over that spectrum.
It's a little bit of a stretch... but I think it might be a meaningful analog. The same principals might say that the best you can do statistically in programming DC's is to program them in proportion to the antigen population. That is what a tumor lysate would do. That is what DCVax-L does, (given the two aforementioned assumptions).
Besides... Linda Lau apparently thought it was the best way to go or she would not have joined the team... for what that is worth.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
